GSK Canada submits respiratory syncytial virus vaccine candidate for regulatory review

GSK

25 November 2022 - Application includes important pivotal Phase 3 data evaluating the efficacy and safety of our vaccine candidate against respiratory syncytial virus-lower respiratory tract disease in adults aged 60 years and above.

GSK has filed a new drug submission to Health Canada for its respiratory syncytial virus older adult vaccine candidate.

Read GSK press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Canada , Vaccine , Dossier